The short version of certificate of analysis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-05. Anything still debated is marked as such rather than presented as settled.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
A major focus in the field of protein engineering is on creating DNA libraries that sample regions of sequence space, often with the goal of finding mutants of proteins with enhanced functions compared to the wild type. These libraries are created either by using a wild type sequence as a template and applying one or more mutagenesis techniques to make different variants of it, or by creating proteins from scratch using artificial gene synthesis. These libraries are then screened or selected, and ones with improved phenotypes are used for the next round of mutagenesis. Protein Sequence space Directed evolution Protein engineering High-dimensional space
=== Spectrometer === Americium-241 has been used as a portable source of both gamma rays and alpha particles for a number of medical and industrial uses. The 59.5409 keV (9.53950 fJ) gamma ray emissions from 241Am in such sources can be used for indirect analysis of materials in radiography and X-ray fluorescence spectroscopy, as well as for quality control in fixed nuclear density gauges and nuclear densometers. For example, this isotope has been employed to gauge glass thickness to help create flat glass. Americium-241 is also suitable for calibration of gamma-ray spectrometers in the low-energy range, since its spectrum consists of nearly a single peak and negligible Compton continuum (at least three orders of magnitude lower intensity).
=== Maternal paracetamol use === On 24 September 2025, the World Health Organization stated there is no conclusive scientific evidence linking paracetamol (acetaminophen) use during pregnancy to autism. Across multiple international health authorities, including the Society of Obstetricians and Gynaecologists of Canada, the Medicines and Healthcare products Regulatory Agency in the UK, and the European Medicines Agency, paracetemol is recommended as the first-line treatment for pain and fever during pregnancy when used at the lowest effective dose for the shortest duration. Current high-quality evidence shows no causal link between prenatal use and autism or other neurodevelopmental disorders, while untreated pain or fever poses risks to both mother and fetus. In 2025, the United States Food and Drug Administration advised physicians to minimize routine acetaminophen use during pregnancy due to unproven links to autism and ADHD, while noting it remains the safest analgesic and antipyretic option in pregnancy compared to alternatives like aspirin and ibuprofen. Very large population-based studies indicate that prenatal paracetamol use is not linked to autism, ADHD, or intellectual disability, and studies comparing siblings suggest that earlier reported links were likely due to other factors, not paracetemol itself.
As early as 1718 letters from the Secretary at War were addressed from "The War Office". His department had several headquarters in London until it settled at Horse Guards in Whitehall during 1722. It remained there until 1858. Then, following the dissolution of the Board of Ordnance, the War Office moved into the Board's former offices in Cumberland House, Pall Mall. Over the ensuing years it expanded into adjacent properties on Pall Mall before it was relocated to purpose-built accommodation, in what is now known as the Old War Office Building, in 1906. Between 1906 and its abolition in 1964 the War Office was based in a large neo-Baroque building designed by William Young, completed during 1906, and located on Horse Guards Avenue at its junction with Whitehall in central London. The construction of the building required five years to complete, at a cost of more than 1.2 million pounds. The building is somewhat oddly shaped, forming a trapezoid to maximise the use of the irregularly shaped plot of land on which it was built: its four distinctive domes were designed as a decorative means of disguising the shape. It has around 1,100 rooms on seven floors. After 1964 the building continued to be used, under the name The Old War Office, by the Ministry of Defence. On 1 June 2007 the building, other than the steps that give access to it, was designated as a protected site for the purposes of Section 128 of the Serious Organised Crime and Police Act 2005. The effect was to make it a specific criminal offence for a person to trespass on the building.
=== Plasmonics and metamaterials === Graphene accommodates a plasmonic surface mode, observed recently via near field infrared optical microscopy techniques and infrared spectroscopy Potential applications are in the terahertz to mid-infrared frequencies, such as terahertz and midinfrared light modulators, passive terahertz filters, mid-infrared photodetectors and biosensors.
Sources: en.wikipedia.org
Within molecular and cell biology, Qa-1b is a MHC class I molecule and is the functional homolog of HLA-E in humans. Qa-1b is characterised by its limited polymorphisms and small peptide repertoire. Qa-1b binds to peptides derived from signal peptides of MHC class Ia molecule and interact with the CD94/NKG2 receptors on natural killer cells. The Qa-1b-peptide complex signals natural killer cells not to engage in cell lysis. Despite its homology with HLA-E, it seems that Qa-1b evolved a similar function to HLA-E coincidentally.
The thoracic cavity is protected by the thoracic wall (comprising the rib cage and associated skin, muscle, and fascia), comprising the mediastinum, heart and great vessels, and the bulk of the respiratory tract. The abdominal cavity, lined by the peritoneum, contains the bulk of the gastrointestinal tract, the spleen and the kidneys. Abdominal organs may be classified as solid organs or hollow organs. The solid organs are the liver, pancreas, spleen, kidneys, and adrenal glands. The hollow organs of the abdomen are the stomach, intestines, gallbladder, bladder, and rectum. The pelvic cavity contains the urinary bladder, internal reproductive organs, and rectum. Viscera are the internal organs of the ventral cavity. The term "visceral" is contrasted with the term "parietal", meaning "of or relating to the wall of a body part, organ or cavity". The two terms are often used in describing a membrane or piece of connective tissue, referring to the opposing sides.
=== Condom use === One Australian study of 184 men looked at penis length and circumference in relation to condom breakage or slippage. 3,658 condoms were used. The study found that when used correctly, condoms had a breakage rate of 1.34% and a slippage rate of 2.05%, for a total failure rate of 3.39%. Penile dimensions did not influence slippage, although penis circumference and broken condoms were strongly correlated, with larger sizes increasing the rate of breakage.
=== Other performance aspects === The evaluation of the performance cannot be considered complete without considering the limit of detection, the range of linear response and the signal reproducibility. EI is known as a low-efficiency ionization technique. Because less than 1/10 000 of the gas-phase sample molecules are ionized, impressive detection limits cannot be expected. However, the efficient interfacing mechanism of this interface allows picogram-level detection limit in selected ion monitoring (SIM) for most substances. On the other hand, soft ionization techniques such as ESI are, in some cases, far more efficient but generate fewer fragment ions. The cost of this attitude is paid in terms of structural information so that a second analyzer to generate MS/MS spectra is an obligation. A typical EI spectrum, in general, has extensive structural information, and a cheaper, single-stage mass spectrometer might be sufficient for analyte characterization or identification. As a rule of the thumb, nanogram-level sensitivity is obtained in full-scan mode for most substances. Linearity and reproducibility are two point of strength of the interface. Up to four orders of magnitude linearity with RSD lower than 10% are common values in many applications.
Protection: One of the main functions of the oral mucosa is to physically protect the underlying tissues from the mechanical forces, microbes and toxins in the mouth. Keratinised masticatory mucosa is tightly bound to the hard palate and gingivae. It accounts for 25% of all oral mucosa. It supports underlying tissues by resisting the loading forces exerted during mastication. Lining mucosa in the cheeks, lips and floor of mouth is mobile to create space when chewing and talking. During mastication, it allows food to move freely around the mouth and physically protects the underlying tissues from trauma. It accounts for 60% of oral mucosa. Secretion: Saliva is the primary secretion of the oral mucosa. It has many functions including lubrication, pH buffering and immunity. The lubricating and antimicrobial functions of saliva are maintained mainly by resting; saliva results in a flushing effect and the clearance of oral debris and noxious agents. Saliva contains numerous antimicrobial proteins that help protect the oral ecosystem from infectious agent. The components like lysozyme, lactoferrin, salivary peroxidase, myeloperoxidase, and thiocyanate concentrations act as a defense mechanism in the saliva. Saliva is secreted from 3 pairs of major salivary glands (parotid, submandibular, sublingual) alongside many minor salivary glands. It also aids the initial chemical digestion of food as it contains the enzyme amylase, responsible for breaking carbohydrates into sugars.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.